SCHEMBL19009974

SCHEMBL19009974

COc1cc(P(c2ccccc2)c2ccccc2)c(-c2c(P(c3ccccc3)c3ccccc3)cc(OC)c(C)c2C)c(C)c1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35
TUBA3E Q6PEY2 1/20 0.35
TUBA1A Q71U36 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1042656 0.83 TUBB4A (0.42) CYP3A4TDP1CA12CA1CA2
SCHEMBL31566366 0.81 CYP3A4 (0.35) CYP3A4TDP1TUBB4ATUBBTUBA3C
SCHEMBL31566365 0.81 CYP3A4 (0.35) CYP3A4TDP1TUBB4ATUBBTUBA3C
SCHEMBL301210 0.81 CYP3A4 (0.35) CYP3A4TDP1TUBB4ATUBBTUBA3C
SCHEMBL30138955 0.80 TDP1 (0.44) CYP3A4TDP1CA12CA1CA2
SCHEMBL28906246 0.80 TDP1 (0.44) CYP3A4TDP1CA12CA1CA2
SCHEMBL12446368 0.78 CYP3A4 (0.42) CYP3A4TDP1MAPTKDM4EALDH1A1
SCHEMBL29597288 0.78 CYP3A4 (0.42) CYP3A4TDP1MAPTKDM4EALDH1A1
SCHEMBL458496 0.76 LMNA (0.40) CYP3A4TDP1CA12CA1CA2
SCHEMBL16005619 0.76 CNR2 (0.41) CYP3A4TDP1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170173572-A1 CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170173572-A1 CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS POF1B, FGFR1, COASY CYP3A4 1057/4885TDP1 4780/4885CA12 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.